Trial Information

Summary: Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS) needed for a clinical research trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study To Access The Efficacy And Safety Of Three Different Doses (275, 550, and 1100 MG) Of Rifaximin Administered BID For Either Two Or Four Weeks in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Study visits include a screening visit and 8 office visits over 16 weeks.

Major Inclusion Criteria:
  • Female or Male at least 18 years old
  • Irritable Bowel Syndrome presenting with diarrhea associated IBS symptoms
As part of the study, you will receive at no cost:
  • Study-related medical care and exams
  • Study-related medication
  • Compensation up to $300.00 for time and travel

Call today if you would like to learn more about this study and to find out if you qualify.

Contact:

Silvia Sanchez, Patient Recruitment Coordinator
Advanced Clinical Research Institute
1211 W. La Palma Ave., Suite 602
Anaheim, CA 92801
Telephone: 714-778-1309 x.227
Fax: 714-778-0667
Email:

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:45:28 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA